Michael A. Mussallem - Jun 9, 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Chairman & CEO, Director
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Jun 9, 2021
Transactions value $
-$2,184,549
Form type
4
Date filed
6/9/2021, 08:05 PM
Previous filing
May 25, 2021
Next filing
Jul 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $980K +45.1K +23.96% $21.76 233K Jun 9, 2021 Direct F1
transaction EW Common Stock Gift $0 -12.5K -5.36% $0.00 221K Jun 9, 2021 Direct
transaction EW Common Stock Sale -$3.16M -32.6K -14.76% $97.23 188K Jun 9, 2021 Direct F1, F2
transaction EW Common Stock Gift $0 +12.5K +0.4% $0.00 3.16M Jun 9, 2021 By Living Trust
holding EW Common Stock 372K Jun 9, 2021 401(k) F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -45.1K -8.33% $0.00 496K Jun 9, 2021 Common Stock 45.1K $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $96.8350 to $97.7900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.